Association between metabolic syndrome, diabetes mellitus and prostate cancer risk

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 2, 2013, Pages 181-186

  Lawrence, Y R ^a,b   Morag, O ^a   Benderly, M ^c,d   Boyko, V ^a   Novikov, I ^c   Dicker, A P ^b   Goldbourt, U ^a,d   Behar, S ^a,d   Barchana, M ^e   Wolf, I ^d,f  

^a SHEBA MEDICAL CENTER   (Israel)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY OF HAIFA   (Israel)

^f TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

diabetes mellitus; metabolic syndrome; obesity

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84882455678     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.54     Document Type: Article

References (45)

1. Kris MG, Benowitz SI, Adams S, Diller L, Ganz P, Kahlenberg MS et al. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 2010; 28: 5327-5347.
2. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006; 107: 28-36. (Pubitemid 43941640)
3. Stocks T, Lukanova A, Johansson M, Rinaldi S, Palmqvist R, Hallmans G et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes 2008; 32: 304-314. (Pubitemid 351271779)
4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428. (Pubitemid 40523737)
5. Bjorge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 2010; 171: 892-902.
6. Kabat GC, Kim M, Chlebowski RT, Khandekar J, Ko MG, McTiernan A et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 2046-2053.
7. Coughlin S. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159: 1160-1167. (Pubitemid 38747263)
8. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 2005; 6: 103-111. (Pubitemid 40197704)
9. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056-2062. (Pubitemid 44877026)
10. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004; 47: 1071-1078. (Pubitemid 38918167)
11. Hsing AW, Sakoda LC, Chua Jr. S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86: s843-s857.
12. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006; 17: 989-1003. (Pubitemid 44290764)
13. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21-27.
14. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E et al. Rationale and design of a secondary prevention trial of increasing serum highdensity lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993; 71: 909-915. (Pubitemid 23118060)
15. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
16. Barchana M, Liphshitz I, Rozen P. Trends in colorectal cancer incidence and mortality in the Israeli Jewish ethnic populations. Fam Cancer 2004; 3: 207-214. (Pubitemid 39491736)
17. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
18. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
19. Kohl M, Heinze G. PSHREG: A SASr macro for proportional and nonproportional substribution hazards regression with competing risk data Vienna, 2012, Technical Report.
20. Kasper J, Giovannucci EA. Meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidem Biomarker Prev 2006; 15: 2056-2062. (Pubitemid 44877026)
21. Southern DA, Faris PD, Brant R, Galbraith PD, Norris CM, Knudtson ML et al. Kaplan-Meier methods yielded misleading results in competing risk scenarios. J Clin Epidemiol 2006; 59: 1110-1114. (Pubitemid 44374316)
22. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004; 47: 1-8.
23. Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis 2012 (e-pub ahead of print 2 October 2012).
24. Zhang F, Yang Y, Skrip L, Hu D, Wang Y, Wong C et al. Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Acta Diabetol 2012; 49 (Suppl): 235-246.
25. Long XJ, Lin S, Sun YN, Zheng ZF. Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. Asian Pac J Cancer Prev 2012; 13: 4097-4100.
26. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012; 7: e33411.
27. Marshall JG, Cowell JM, Campbell ES, McNaughton DB. Regional variations in cancer screening rates found in women with diabetes. Nurs Res 2010; 59: 34-41.
28. Kraja AT, Borecki IB, North K, Tang W, Myers RH, Hopkins PN et al. Longitudinal and age trends of metabolic syndrome and its risk factors: the Family Heart Study. Nutr Metab 2006; 3: 41.
29. Laakso M, Pyorala K. Age of onset and type of diabetes. Diabetes Care 1985; 8: 114-117. (Pubitemid 15044006)
30. Various. Entry Metabolic syndrome. Wikipedia, 2012 (accessed 29 November 2012).
31. Vazquez G, Duval S, Jacobs Jr. DR, Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiol Rev 2007; 29: 115-128. (Pubitemid 47229644)
32. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B et al. Metformin and cancer risk in diabetic patients: a systematic review and metaanalysis. Cancer Prev Res 2010; 3: 1451-1461.
33. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170-183. (Pubitemid 351480553)
34. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149: W483-468.
35. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004; 13: 1646-1650. (Pubitemid 39331887)
36. Lund Haheim L, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006; 164: 769-774. (Pubitemid 44522081)
37. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006; 164: 1094-1102. (Pubitemid 44851745)
38. Martin R, Vatten L, Gunnell D, Romundstad P, Nilsen T. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 2009 1-12.
39. Wallner LP, Morgenstern H, McGree ME, Jacobson St DJ, Sauver JL, Jacobsen SJ et al. The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int 2011; 107: 929-935.
40. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev 2010; 19: 2088-2096.
41. Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007; 109: 875-881. (Pubitemid 46333529)
42. Tuohimaa P, Tenkanen L, Syvala H, Lumme S, Hakulinen T, Dillner J et al. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidem Biomarker Prev 2007; 16: 302-307. (Pubitemid 46383350)
43. Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, Rundle A, Bock CH, Tang D et al. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 2009; 74: 185-190.
44. De Nunzio C, Freedland SJ, Miano R, Trucchi A, Cantiani A, Carluccini A et al. Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011.
45. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012; 35: 2402-2411.